Group 1 - The report highlights the significant increase in the prevalence of allergic diseases globally since the 21st century, attributed to environmental issues and lifestyle changes, with the WHO identifying allergies as one of the three major diseases to focus on in this century [2][3] - Approximately 20% to 30% of the global population suffers from allergic diseases, including 300 million asthma patients and 400 million with allergic rhinitis, with China reporting around 40% of its population affected by allergies [3][4] Group 2 - The global allergy diagnostics market is projected to reach 38.94 billion yuan in 2024 and 71.85 billion yuan by 2030, with a compound annual growth rate (CAGR) of 10.75% from 2024 to 2030 [4][10] - Traditional allergy testing methods are categorized into in vivo and in vitro tests, with skin prick tests being the most widely used in vivo method due to its simplicity, low cost, and high safety [4][5] - In vitro testing methods, such as serum total IgE and sIgE testing, are gaining popularity for their safety and precision, with various techniques like immunofluorescence and enzyme-linked immunosorbent assays being utilized in China [9][10] Group 3 - The demand for allergy diagnostics is expected to rise due to the increasing prevalence of allergic diseases and the low current diagnosis rates in China, which may lead to a significant market expansion as public awareness grows [10][12] - Advances in research and technology, such as microfluidic technology and specific IgE testing, are anticipated to enhance the accuracy and efficiency of allergy diagnostics, potentially altering the market landscape [10][12] - A trend towards domestic alternatives to imported allergy testing products is emerging in China, driven by improvements in local companies' R&D capabilities and government support [12]